LIVECAST Markets Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Live News EQUITY FLASH L impact Oct 02, 2026, 12:24 AM UTC

ARK Investment buys 159K Veracyte shares

Cathie Wood's ARK Investment bought 159K shares of Veracyte today.

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

No ticker tags on this item.

Related stories

Orexo to fund expected US DOJ settlement with rights issue Orexo flagged an expected settlement payment tied to a matter involving the US Department of Justice, subject to a final settlement agreement. A planned rights issue targets about M impact | EQUITY | Oct 06, 2026, 06:06 AM UTC Top S&P 500 Stock Names Implied Volatility L impact | EQUITY | Oct 06, 2026, 06:02 AM UTC Allegion Acquires Privately Held Overly Door, Terms Undisclosed Allegion plc (ALLE) announced its acquisition of privately held Overly Door Company. The financial terms of the transaction were not disclosed. M impact | EQUITY | Oct 06, 2026, 06:02 AM UTC ANDRITZ sets new 2029 financial targets: 10 BEUR revenue, 10% EBITA margin ANDRITZ is hosting its Capital Markets Day 2026 and announced new medium-term financial targets for 2029, aiming for 10 billion euros in revenue and a 10% comparable EBITA margin. M impact | EQUITY | Oct 06, 2026, 06:01 AM UTC Orexo Plans SEK 250M Rights Issue With 70% Backstop Orexo AB (publ) plans a rights issue of approximately SEK 250M, pending EGM approval. About 70% of the issue is covered by subscriptions and underwriting. The company had SEK 118.7 M impact | EQUITY | Oct 06, 2026, 06:01 AM UTC Orion Pharma to commercialize Qilu's pembrolizumab biosimilar in Europe Orion Pharma has signed an agreement with Qilu Pharma Europe to distribute, market, and sell an intravenous pembrolizumab biosimilar across Europe. Qilu will supply the biosimilar M impact | EQUITY | Oct 06, 2026, 06:01 AM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.